despit
first
report
year
engraft
syndrom
es
remain
variabl
defin
complic
follow
hematopoiet
progenitor
cell
transplant
hpct
es
typic
character
occurr
new
noninfecti
fever
coincid
neutrophil
engraft
fever
may
associ
skin
rash
diarrhea
pulmonari
infiltr
hepat
dysfunct
although
case
es
prolong
caus
sever
symptom
necessit
use
corticosteroid
underli
pathophysiolog
associ
es
remain
poorli
understood
base
lewi
rat
syngen
autolog
hpct
es
gener
believ
arisen
due
interplay
cytokin
interleukin
il
tumor
necrosi
factor
tnf
interferon
ifn
associ
hematopoiet
recoveri
set
defici
reg
cell
mani
studi
examin
factor
predispos
patient
es
despit
es
associ
signific
morbid
pauciti
studi
examin
impact
health
resourc
util
set
determin
retrospect
studi
es
follow
autolog
hpct
affect
hospit
use
intraven
antimicrobi
addit
radiolog
examin
financi
cost
transplant
patient
demograph
clinic
data
diagnosi
treatment
histori
collect
electron
medic
record
cost
care
transplant
obtain
account
depart
medic
center
studi
approv
institut
review
board
new
york
medic
collegewestchest
medic
center
transplant
carri
inpati
basi
high
effici
particul
air
filter
singl
room
use
autolog
peripher
blood
stem
cell
autolog
peripher
blood
stem
cell
mobil
use
plerixafor
mgkg
chemotherapi
patient
receiv
start
day
prophylact
ciprofloxacin
fluconazol
acyclovir
absolut
neutrophil
count
drop
less
weekli
surveil
cytomegaloviru
detect
pcr
perform
patient
detect
threshold
iuml
iuml
defin
fever
oral
temperatur
fever
occur
day
day
consid
fever
new
fever
occur
day
day
discharg
consid
fever
neutrophil
engraft
defin
attain
absolut
neutrophil
count
three
consecut
day
consecut
patient
underw
peripher
blood
hpct
hematolog
malign
april
decemb
identifi
male
femal
median
age
year
rang
common
diagnosi
multipl
myeloma
follow
lymphoma
hodgkin
diseas
patient
receiv
regimen
prior
transplant
prepar
regimen
use
hpct
melphalan
rituxan
day
bcnu
day
etoposid
day
day
melphalan
day
beam
patient
divid
three
group
accord
occurr
fever
group
fever
group
fever
group
fever
statist
differ
found
among
three
group
age
sex
distribut
dose
cell
infus
underli
diagnosi
prior
use
bortezomib
transplant
prepar
regimen
dose
per
kg
bodi
weight
patient
fever
show
evid
neutrophil
engraft
within
h
develop
fever
fourteen
patient
develop
fever
period
patient
develop
fever
patient
develop
fever
fever
microbi
organ
isol
patient
fever
toxigen
c
difficil
commonest
n
follow
enterococci
n
cytomegaloviru
n
viremia
coronaviru
n
epidermidi
n
staph
aureu
n
corynebacterium
jeikeium
n
like
epidermidi
contamin
bacteri
isol
obtain
blood
cultur
except
toxigen
c
difficil
detect
pcr
diarrheal
stool
differ
likelihood
posit
microbi
isol
two
group
patient
fever
two
group
patient
fever
patient
fever
p
patient
develop
fever
significantli
longer
hr
ci
p
compar
develop
fever
figur
median
day
rang
ci
group
without
fever
day
rang
ci
group
fever
p
third
quartil
group
without
fever
day
fever
day
p
differ
two
group
predominantli
due
increas
fever
figur
statist
differ
group
without
fever
group
fever
howev
median
fever
significantli
longer
compar
without
fever
day
vs
day
hr
ci
p
earli
onset
fever
vs
hr
ci
p
next
determin
impact
es
first
use
follow
criteria
es
occurr
new
fever
associ
microbi
isol
infect
occur
hour
neutrophil
engraft
associ
skin
rash
pulmonari
infiltr
diarrhea
new
abnorm
liver
function
test
twenti
case
es
occur
cohort
patient
howev
includ
eight
patient
noninfecti
fever
whose
fever
probabl
due
es
even
though
fever
associ
rash
diarrhea
pulmonari
infiltr
abnorm
liver
function
test
incid
es
went
far
es
commonest
caus
new
fever
occur
day
respons
fever
es
result
significantli
longer
compar
without
fever
p
hr
ci
figur
median
patient
es
day
ci
compar
day
ci
without
fever
p
final
examin
impact
es
intraven
antimicrobi
usag
addit
radiolog
examin
financi
cost
transplant
use
incur
group
patient
without
fever
point
refer
cutoff
determin
resourc
util
cutoff
incur
patient
develop
es
addit
longer
es
led
increas
intraven
antimicrobi
day
averag
days
patient
furthermor
addit
chest
examin
averag
patient
three
tomograph
scan
chest
abdomen
pelvi
carri
among
patient
develop
es
total
expenditur
incur
es
patient
bill
record
avail
averag
esday
conclus
es
occur
frequent
autolog
hpct
es
increas
morbid
also
resourc
util
identif
biomark
use
help
diagnos
es
highli
desir
patient
undergo
unnecessari
investig
addit
antimicrobi
therapi
consequ
result
longer
higher
transplant
cost
elev
protein
crp
found
associ
howev
crp
highli
nonspecif
also
elev
sepsi
complic
requir
aggress
antimicrobi
therapi
group
immunocompromis
patient
serum
procalcitonin
robust
biomark
sepsi
futur
studi
may
examin
combin
crp
procalcitonin
diagnosi
es
exclus
sepsi
patient
low
procalcitonin
accompani
elev
crp
confid
diagnos
es
spare
addit
investig
prolong
cours
intraven
antimicrobi
therapi
symptom
associ
es
